N
NexEos Bio
Non-invasive imaging agent for diagnosing and managing Eosinophilic Esophagitis, enhancing patient care and disease monitoring
About NexEos Bio
NexEos Bio is a biotechnology company focused on developing innovative technologies to diagnose and treat eosinophil-mediated diseases. The company's primary product, NDX33o, is a novel, non-invasive imaging agent designed for the diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE). This imaging agent helps healthcare providers better understand and manage the inflammation associated with EoE, ultimately improving patient outcomes and quality of life. NexEos Bio operates in the biopharmaceutical market, targeting healthcare providers and patients suffering from eosinophil-related conditions. The company's business model revolves around the development and commercialization of its proprietary imaging agents, generating revenue through product sales and potential partnerships with healthcare institutions and pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Founded
- 2019
- Headquarters
- Pottstown, United States
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning NexEos Bio.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Altitude Lab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NexEos Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NexEos Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.